ArticleDiscover oncology2025
Transcriptomic and functional analysis of triphenyl phosphate exposure in prostate cancer progression.
Article in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundProstate cancer is a common malignancy in men with variable clinical outcomes. While therapeutic options have improved, the potential impact of environmental chemicals such as Triphenyl phosphate (TPP)-a widely used organophosphorus flame retardant-on prostate cancer progression remains poorly understood.
methodsWe conducted transcriptomic profiling using mRNA sequencing to investigate gene expression changes in prostate cancer cells following TPP exposure. Subsequent analyses, including single-sample gene set enrichment analysis (ssGSEA) and data mining from the Comparative Toxicogenomics Database (CTD), were performed to identify TPP-associated genes. TCGA-based survival modeling was used to evaluate the prognostic relevance of selected genes. Functional assays were carried out to assess TPP-induced phenotypic changes.
resultsExposure to 0.1 µM TPP significantly enhanced prostate cancer cell proliferation and invasion. Transcriptomic analysis revealed 521 upregulated and 964 downregulated genes post-treatment. Key prognostic markers, including TTK, S100A9, MACIR, AKR1B10P1, and ZFPM2-AS1, were identified and found to be associated with poor patient survival. GSEA further revealed that these genes are enriched in pathways related to metabolism and cancer progression.
conclusionOur findings suggest that TPP exposure may promote malignant phenotypes in prostate cancer cells by altering gene expression and activating cancer-associated pathways. This study underscores the potential health risks of environmental pollutants and highlights candidate prognostic biomarkers in prostate cancer.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.